February 13, 2026 - 05:05

A wave of apprehension surrounding artificial intelligence has recently swept through the financial sector, pulling down shares of major firms like Charles Schwab. This sell-off appears linked to broader market anxieties about AI's disruptive potential, though the immediate impact on these established companies' fundamentals remains less clear.
Analysts suggest the reaction may be overblown, creating a potential window for investors. While AI will undoubtedly transform the industry over time, current valuations for many top financial institutions now look increasingly attractive. These companies possess strong balance sheets, proven business models, and are themselves adopting AI to improve efficiency and client services.
The key for investors is differentiation. The market has painted the sector with a broad brush, but not all firms are equally exposed. For long-term investors, this period of uncertainty may present a chance to acquire shares in quality financial businesses at a discount, betting on their resilience and adaptive capabilities in the face of technological change. The current fear, in this view, has outpaced the foreseeable reality.
March 30, 2026 - 00:03
Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth PlansBiotechnology company Halozyme Therapeutics has announced a key leadership transition, appointing David Ramsay as its interim Chief Financial Officer. The move comes as the firm continues to...
March 29, 2026 - 09:37
SpaceX And Anthropic IPO Frenzy Begins Early As REX Shares, Tuttle Capital File For 2x Leveraged ETFsA race to capitalize on the anticipated public offerings of two tech giants has officially begun, with investment managers filing for specialized funds well before the companies even set a listing...
March 28, 2026 - 20:26
Adobe’s (ADBE) Selloff Isn’t a Buy-the-Dip Opportunity YetAdobe`s stock has experienced a significant downturn, plummeting over 60% from its 2021 high. This dramatic sell-off represents one of the steepest declines the company has faced in recent years....
March 28, 2026 - 04:19
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational HighlightsCalidi Biotherapeutics has announced significant strides across its clinical pipeline and operational strategy, highlighted by a new partnership and key regulatory feedback. The company has entered...